A Randomized, Double-blind, Multicenter, Multinational, Active-controlled, Parallel-designed Phase 3 Clinical Trial to Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24months to 15yrs
Latest Information Update: 15 Nov 2022
At a glance
- Drugs BR-8003 (Primary)
- Indications Hepatitis A
- Focus Registrational; Therapeutic Use
- Sponsors Boryung Biopharma
Most Recent Events
- 15 Nov 2022 New trial record